Table 6.
Post-Admission Treatment Measures in Severe COVID-19 Patients
| All patients (n=371) |
MP 40 mg/d (n = 243) |
DEX 5 mg/d (n = 128) |
P-value | |
|---|---|---|---|---|
| Antiviral drugs | 152(41%) | 107(44%) | 45(35.2%) | 0.098 |
| Azvudine tablet | 106(28.6%) | 72(29.6%) | 34(26.6%) | 0.534 |
| Paxlovid | 69(18.6%) | 43(17.7%) | 26(20.3%) | 0.538 |
| Anticoagulant drug | 168(45.3%) | 104(42.8%) | 64(50%) | 0.185 |
| Antibacterial drug | 355(95.7%) | 235(96.7%) | 120(93.8%) | 0.182 |
| Antifungal agents | 52(14%) | 34(14%) | 18(14.1%) | 0.985 |
| IVIG | 32(9.2%) | 24(9.9%) | 10(7.8%) | 0.083 |
| Anti-fibrotic drug | 5(1.3%) | 4(1.6%) | 1(0.8%) | 0.492 |
| Oxygen inhalation | 359(96.8%) | 237(97.5%) | 122(95.3%) | 0.354 |
| Nasal cannula for oxygen | 311(83.8%) | 208(85.6%) | 103(80.5%) | 0.202 |
| Mask oxygen therapy | 60(16.2%) | 31(12.8%) | 29(22.7%) | 0.014 |
Abbreviation: IVIG, Intravenous Immunoglobulin.